Cardlytics, Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

CDLX$1.82-6.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations (Unaudited)

(Amounts in thousands, except per share amounts)

	Three Months EndedMarch 31,
	2026	2025
Revenue	$34,319	$56,435
Costs and expenses:
Partner Share and other third-party costs	14,597	29,104
Delivery costs	2,581	5,786
Sales and marketing expense	6,761	10,382
Research and development expense	6,430	10,278
General and administrative expense	8,281	12,943
Change in contingent consideration	—	60
Gain on divestiture	—	(5,350)
Depreciation and amortization expense	3,943	4,347
Total costs and expenses	42,593	67,550
Operating loss	(8,274)	(11,115)
Other income (expense):
Interest expense, net	(2,533)	(1,830)
Loss on investment	(1,285)	—
Foreign currency (loss) gain	(1,706)	2,627
Total other income (expense)	(5,524)	797
Loss before income taxes from continuing operations	(13,798)	(10,318)
Income tax benefit	—	—
Loss from continuing operations	(13,798)	(10,318)
Income (loss) from discontinued operations	9,318	(2,964)
Net loss	$(4,480)	$(13,282)
Net (loss) income per share, basic and diluted:
Continuing operations	$(0.25)	$(0.20)
Discontinued operations	$0.17	$(0.06)
Weighted-average common shares outstanding, basic and diluted	54,896	51,863

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.